VASCULAR
hamburger
product photo

ABSORB: THE WORLD’S FIRST FULLY BIORESORBABLE VASCULAR SCAFFOLD

absorb

Large Clinical Program and Real World Use

absorb img

*Small platinum markers near scaffold edges remain.

**Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU

1. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060
2. Yamaji, K., et al. Very Long-Term Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation, Circ Cardiovasc Interv. 2010: DOI; 10.1161/CIRCINTERVENTIONS.110.958249
3. Petronio, S, IT-DISAPPEARS, EuroPCR 2016
4. Hernandez, F., REPARA, PCR 2016
5. Cortese, B RAI Registry, PCR 2016
6. Koning, R France ABSORB, PCR 2016
7. Hamm, C., GABI-R, EuroPCR2016;
8. Serruys, P.W., et al. TROFI II, Eur Heart J.2015; DOI: 10.1093/eurheartj/ehv500;
9. DeLaTorre Hernandez, J., ESTROFA-BVS, EuroPCR2015;
10. Ellis, S., et al. ABSORB III 1-Year, New Engl J Med. 2015; DOI:1056/NEJMoa1509038;
11. Kimura, T., et al. ABSORB Japan, Eur Heart J. 2015; DOI:10.1093/eurheartj/ehv435;
12. Gao, R., et al. ABSORB China, J Am Coll Cardiol. 2015; DOI:1016/j.jacc.2015.09.054.;
13. Capodanno, D., et al. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everoliumus-Eluting Stents, A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries., JACC : Cardiovascular Interventions 2016; DOI: 10.1016/j.jcin.2015.10.042;
14. Chevalier, B., ABSORB II, TCT2015;
15. Bartorelli, A., ABSORB Extend, TCT 2015;
16. Schwenke, ASSURE, TCT2015;
17. Sales data through May 2016, 1.2 units/patient, Data on file at Abbott Vascular
18. Clinical Studies through 2016.
19. AIDA, EVERBIO, ABSORB II, ABSORB III, ABSORB IV, ABSORB Japan, ABSORB China, COMPARE Absorb, Trofi II, Prospect II, ISAR Absorb, PREVENT
20. ABSORB First, ABSORB Extend, Gabi–R, REPARA, UK registry, IT-Disappears, France ABSORB, FEAST.RU, RAI Registry, SMART REWARD, ABSORB Australia, BVS EXPAND, ASSURE, PABLOS, Absorb CTO, Prague – 19, GHOST Ferrarotto, POLAR ACS, GHOST EU. Cohort B.

ABSORB GT1: BIORESORBABLE VASCULAR SCAFFOLD (BVS) SYSTEM

The Absorb GT1 (Absorb) BVS is a cutting-edge advance in percutaneous coronary intervention (PCI). This breakthrough technology repairs and revascularizes like the best-in-class XIENCE drug-eluting stent. Unlike a drug-eluting stent that is a permanent metallic implant, Absorb is naturally resorbed in the body, leaving nothing* behind.

The Absorb bioresorbable technology offers more than a device-free artery. Absorb also restores** vasomotor function and pulsatility1, allowing the artery to more naturally regulate blood flow.

ALLOWS RESTORATION THROUGH MECHANICAL CONDITIONING AND BIORESORPTION

  • Drug elution timed like XIENCE to match restenosis cascade
  • Loss of mechanical support permits mechanical conditioning of tissue to promote healing2
  • Full mass loss at approximately 3 years to enable neomedia formation and natural function3

absorb

ABSORB GT1 PRODUCT DESIGN ELEMENTS

absorb

 

1. Serruys, P.W.,et al. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis, 5-Year Follow-Up, J Am Coll Cardiol. 2016; DOI: 10.1016/j.jacc.2015.11.060
2. Wijns W, et al. CCI. 2008; Circ Cardiovasc Interv 2008;1;193-200. Wijns, W, et al. JACC. June. 2008; doi:10.1016/j.jacc.2007.12.059.
3. Courtesy of Dr. R.J. van Geuns, Rotterdam, The Netherlands; De Bruyne, B. ABSORB Cohort B 5-year, TCT 2014.
* Small platinum markers at scaffold edge remain for fluoroscopic landmarking.
**Absorb improves coronary luminal diameter, restores blood flow and enables movement of the treated vessel. Source: Absorb GT1 IFU
† Improved as compared to Absorb BVS. Tests performed by and data on file at Abbott Vascular.
+ XIENCE family of products: XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine.

absorb

ABSORB III MET PRIMARY ENDPOINT FOR FDA APPROVAL1

absorb

ABSORB III DEVICE THROMBOSIS AT 1 YEAR2

Appropriate vessel sizing – using Absorb in arteries with a reference vessel diameter (RVD) of ≥ 2.25 mm – revealed thrombosis rates similar to those with XIENCE.

absorb

LONG-TERM BENEFITS: SIGNALS OF REDUCED LONG-TERM EVENTS WITH ABSORB3

absorb

ABSORB: DEMONSTRATED SIGNIFICANT LATE LUMEN GAIN AT 6/7 YEARS4

absorb

1. Ellis, S., et al. ABSORB III 1-Year, New Engl J Med. 2015; DOI:1056/NEJMoa1509038;
2. Kereiakes, D,. ABSORB III TCT 2015
3. Serruys, P, ABSORB Cohort B TCT 2015
4. Serruys, P, ABSORB Cohort B EuroPCR 2016

absorb

PSP FOR OPTIMAL ABSORB IMPLANTATION

absorb

LEARNINGS FROM ABSORB CLINICAL EXPERIENCE: PROPER IMPLANTATION TECHNIQUE LOWERS ST RATES1

absorb

1. Puricel, S. et l. J Am Coll Cardiol. 2016; 67(8):921–31

absorb

ORDERING INFORMATION

absorb

absorb

absorb

AP2937989-WBO Rev. D

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

YESNO